EyeGate Announces Interim Data From Phase 1b / 2a Clinical Trial of Iontophoretic EGP-437 Ophthalmic Solution in Macular Edema ...
WALTHAM, Mass., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or the "Company"), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery …